anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A wireless sensor device for wireless transmission of sensed medical data to a medical monitoring and/or intervention device. The sensor device has a sensor element for sensing a physical parameter related to the body of a living human or animal. A wireless RF transmitter and receiver for transmitting and also receiving data packets having the sensed physical parameters according to a TDMA-based network protocol. The processor system controls the following operations of the wireless RF transmitter and receiver, including: the sensor device may operate as a wireless RF synchronization master or a wireless RF synchronization slave, and if no master is detected as being available, the sensor device may negotiate according to a deterministic negotiation algorithm to assign one of a plurality of wireless RF devices connected to a TDMA-based network as the wireless RF synchronization master. This allows a self-healing network, since one of the slave devices present in a network session can also be assigned as a new master, even if the master device is out of range or switched off. This provides a reliable and low latency wireless RF network for medical systems, e.g., for Continuous Positive Air Pressure (CPAP) devices, which can utilize sensed data from one or more sensor devices to control their blower to provide the appropriate air pressure.
A method of treating increased non-LTR retrotransposition in a cell. The method includes exposing a neural cell to a retrotransposition inhibitor in an amount sufficient to decrease the non-LTR retrotransposition in the neural cell or a progeny of the neural cell. In various embodiments, the non-LTR retrotransposition involves at least one Ll retrotransposon. Also provided is a method of assaying retrotransposition in neural cells. The method includes sorting synchronized neural cells of the same genetic background into single neural cells, and subjecting one or more of the sorted single neural cells to quantitative polymerase chain reaction amplification of at least one retrotransposon. In addition, a method of identifying an inhibitor of retrotransposition and a identifying a neural condition associated with non-LTR retrotransposition are provided.
BACKGROUND: Impaired sensitivity to thyroid hormones (TH) was associated with metabolic syndrome. The study aimed to explore the association between central TH sensitivity indices and insulin resistance (IR) in euthyroid adults with obesity.
METHODS: This cross-sectional study enrolled 293 euthyroid outpatients with obesity in Beijing Chao-Yang Hospital. We used the thyroid feedback quantile-based index (TFQI), thyroid stimulating hormone index (TSHI), and thyrotrophic T4 resistance index (TT4RI) to indicate central TH sensitivity. IR was assessed by homeostasis model assessment of insulin resistance (HOMA-IR), hepatic insulin resistance index (hepatic-IR), the Matsuda index, and the adipose tissue insulin resistance index (Adipo-IR). Participants were categorized according to tertiles of TH sensitivity indices. We used multiple linear regressions to explore the associations.
RESULTS: There was a significant stepwise increase in HOMA-IR and Adipo-IR from the lowest to the highest tertiles of TH sensitivity indices (all P<0.05). After adjustment for age, sex, body mass index, hypertension, hyperlipidemia, and diabetes, only Adipo-IR was significantly associated with TH sensitivity indices. On average, each unit increased in TFQI, TSHI, and TT4RI was associated with 1.19 (P=0.053), 1.16 (P=0.04), and 1.01 (P=0.03) units increased in Adipo-IR, respectively. There was no significant association between TH sensitivity indices and HOMA-IR, hepatic-IR, and the Matsuda index after adjustment for other risk factors.
CONCLUSIONS: Reduced central TH sensitivity was associated with increased adipose tissue insulin resistance in euthyroid adults with obesity. The results further confirmed the importance of TH sensitivity on metabolic diseases.
The invention relates to a method for obtaining scutellarin from a thymus plant. The extractive is derived from labiatae thymus plant. Particularly, high-purity scutellarin is prepared by taking thymus quinquecostatus, thymus quinquecostatus var. przewalskii, thymus quinquecostatus var. asiaticus, thymus mongolicus or thymus altaicus as a raw material through processing steps such as solvent extraction, macroporous resin separation, and recrystallization. The scutellarin can treat cardiovascular and cerebrovascular diseases such as acute myocardial infarction, ischemic cerebrovascular disease, coronary heart disease, and angina pectoris. The preparation method has abundant raw material resources, simple technology, and low cost. The requirement of the medical market for scutellarin can be satisfied. Non-volatilizing parts of the thymus plant, such as thymus quinquecostatus, thymus quinquecostatus var. przewalskii, thymus quinquecostatus var. asiaticus, thymus mongolicus or thymus altaicus can be developed, so that many things can be achieved at one stroke, and the method has a bright industrial application prospect.
PROBLEM TO BE SOLVED: To improve size accuracy by forming a plaster composition for manufacturing a fire-resistant plaster model with fused silica, white cement, and a plaster-containing object of specific pts.wt. respectively. SOLUTION: A plaster composition is constituted of fused silica 45-58 pts.wt., white cement 0.1-1.5 pts.wt., and a plaster-containing object 40-50 pts.wt., and it can contain a filler additionally within the range not impairing the effect. A plaster die 1 having a projection 1a is formed with this plaster composition, it is supported on a base 2 to form the fire-resistant plaster die 1. The wet compressive strength of the plaster die 1 is preferably set to 15 MPa or above. The crown-like section 3a of a crown-like molding 3 is fitted on the outer periphery of the projection 1a of the plaster die 1. Slurry is prepared from ceramic powder and water, it is built up on the plaster die 1 and molded by the condense method, and it is primarily baked to obtain a ceramic porous body. It is impregnated with glass to obtain a dental porcelain frame. Size accuracy can be then improved.
Unilateral (right) IPP-PSP block with 30 mL normal saline 0.9%, administered after the closure of the wounds. Unilateral (right) IPP-PSP block with 30 mL normal saline 0.9%, administered after the closure of the wounds. The IPP-PSP block procedure will be carried out as described in the Active Comparator.
Primary aldosteronism (PA) is one of the most common causes of secondary hypertension, and its most common subtypes are aldosterone-producing adenoma and idiopathic hyperaldosteronism, which account for 95% to 98% of PA. Subtype diagnosis is crucial for the treatment of primary aldosteronism, which conducts the appropriate treatment strategy. Currently, adrenal venous sampling (AVS) serves as the gold standard for subtyping of PA. At present, almost all medical centers use the femoral vein approach for AVS, and most studies report that the success rate is 30%-80%.How to improve the success rate of AVS has been a hot topic in the field of primary aldosteronism. Our research team is the first in the world to conduct AVS via an antecubital approach. The previous study found that the success rate of AVS via this approach can reach to 88.0%, with a low incidence of complications. In this study, patients with primary aldosteronism who meet the indications of AVS will be randomly assigned to antecubital approach group and femoral approach group. Clinical, laboratory and examination data will be recorded and the success rate and safety of AVS via antecubital and femoral approach will be compared.
Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy. Placebo gum was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. The placebo gum (manufactured by Fertin Pharma A/S, Vejle, Denmark) contained 2.6% cayenne pepper to simulate the taste of nicotine. Use of the gum was encouraged for 24 weeks.
Bipolar disorder is associated with alterations of chemicals in the brain, including one named serotonin. Treatment of depression in bipolar disorder can be accomplished by increasing serotonin function by medications named selective serotonin reuptake inhibitors (SSRI's). Serotonin signals in the brain occur through receptors in a way that is similar to a lock and key, where serotonin is a key and the receptor is a lock. One important receptor is the serotonin 1A (5-HT1A) receptor. This receptor has been found to be abnormal in bipolar disorder during periods of depression, as measured by a type of brain imaging called positron emission tomography (PET). The amount of brain 5-HT1A receptor measured by imaging has also been associated with how well depressed patients with major depressive disorder respond to an SSRI medication. This project will measure the 5-HT1A receptors in bipolar depressed individuals using PET with the radiotracer \[11C\]-CUMI-101 and will evaluate the ability of this brain imaging signal to predict how patients respond to SSRI treatment when added to a mood stabilizer.
DESCRIPTION: Sodium Pertechnetate Tc 99m Injection, as eluted according to the elution instructions with Lantheus Medical Imaging, Inc. TECHNELITE®, Technetium Tc 99m Generator, is in 0.9% Sodium Chloride Injection, USP as a sterile, non-pyrogenic, diagnostic radiopharmaceutical suitable for intravenous injection and direct instillation. The pH is 4.5-7.5. The eluate should be clear, colorless, and free from visible foreign material. Each eluate of the TECHNELITE®, Technetium Tc 99m Generator should not contain more than 0.0056MBq (0.15 microcuries) of Molybdenum Mo99 per 37MBq (1 millicurie) of Technetium Tc 99m per administered dose at the time of administration, and not more than 10 micrograms of aluminum per milliliter of the Technetium Tc 99m Generator eluate, both of which must be determined by the user before administration. Since the eluate does not contain an antimicrobial agent, it should not be used later than one (1) working day after the elution (12 hours).

Lantheus Medical Imaging, Inc. TECHNELITE®, Technetium Tc 99m Generator consists of a column containing uranium fission produced Molybdenum Mo99 adsorbed on alumina. The terminally sterilized and sealed column is enclosed in a lead shield; the shield and other components are sealed in a cylindrical plastic container with an attached handle. Built into the top surface are two recessed wells marked SALINE CHARGE and COLLECT. Needles protruding from these two wells accommodate supplied sterile eluant charge vials and sterile eluate collection vials. The eluting solvent consists of 0.9% Sodium Chloride Injection, USP, prepacked into septum-sealed vials, to make the solution isotonic.

The eluate collection vial is evacuated, sterile and non-pyrogenic. A sterile 0.22 micrometer bacteriological filter is incorporated between the column outlet and the collection vials. During and subsequent to elution, the eluate collection vial should be kept in a radiation shield. The Generator is shipped with a silicone needle seal over the charge needle and a vented needle cover over the collect needle. A sterile collect needle seal is supplied for the customer to aseptically reseal the collect needle after each elution.
Retinitis pigmentosa (RP) is an inherited disorder of the photoreceptor cells in the retina. Patients may lose vision since they were young or later in life. Currently, there are more than 60 genes identified as the cause of this condition, one of which, RPE65, has been studied in several gene therapy trials for Leber congenital amaurosis with promising results. Another treatment approach for RP is stem cell therapy. Studies in animal models of RP have shown that subretinal injection of bone marrow-derived mesenchymal stem cells may delay degenerative changes of photoreceptor cells. This is a single arm, single center trial to assess the safety and efficacy of purified adult autologous bone marrow derived CD34+, CD133+, and CD271+ stem cells through a 48 month follow-up period. The combination of these three cell types was based on their diverse potentialities to differentiate into specific functional cell types to regenerate damaged retinal tissue, and the availability of clinical-grade purification system (CliniMACS) and microbeads to purify the target cell populations in clinically-approved methods.
The goal of the EnMP-1 is to enable participants, through a behavioural, psycho-educational intervention, to better manage and understand their fatigue. This program is provided in four, two-hour sessions held weekly.
PURPOSE: Many people with breast cancer (PwBC) experience psychological distress, including fear of cancer recurrence (FCR). Clinical levels of FCR can negatively impact quality of life. While the FCR trajectory may vary according to age, stage at diagnosis, and imminent exams, FCR levels tend to remain relatively stable over time without intervention. Understanding FCR's impact and how PwBC cope with FCR can improve care. This study aimed to explore the nature of FCR and coping mechanisms by analyzing responses to open-ended survey questions from an FCR randomized controlled trial (RCT).
METHODS: This qualitative study was part of a 3-arm RCT for PwBC (N = 390) reporting clinical FCR at eligibility screening. Enrolled PwBC completed a baseline survey, including three open-ended questions regarding FCR experiences. Following thematic analysis, responses were sorted by PwBC's baseline score on the 7-item Fear of Cancer Recurrence (FCR-7) scale, identifying trends by FCR level.
RESULTS: N ≥ 347 PwBC completed the three open-ended survey questions. FCR impacted PwBC's lives across five key domains: emotional, behavioral, cognitive, relational, and professional life. Most identified at least one coping strategy, with strategies consistent across FCR-7 score levels. Higher FCR-7 scores were associated with listing more strategies, tending toward avoidant coping. PwBC sought strategies to improve their sense of purpose, belonging, and control.
CONCLUSION: This study suggests many PwBC with clinical FCR are suffering without adequate means of coping. Clinicians should regularly discuss FCR with survivors. This discussion can foster education about actual risk and ways PwBC could reduce their risk of recurrence.
Background: Anticonvulsant prophylaxis (ACP) for early post-traumatic seizures (PTS) is recommended in patients with traumatic brain injury (TBI). Phenobarbital (PB) may be used to prevent alcohol withdrawal syndrome (AWS) in at-risk patients. The dual-purpose use of PB in the TBI population would allow for consolidation of pharmacotherapy. Objective: The primary objective of this study was to determine the frequency of early PTS in TBI patients at risk of AWS treated with PB as ACP. Secondary objectives included determining rates of over sedation and endotracheal intubation. Methods: Patients received an intravenous (IV) loading dose of PB at 15-20 mg/kg followed by 1 mg/kg every 12 hours for 7 days with a goal level of 15-20 mcg/mL. Medication data, seizure frequency, and episodes of over sedation and endotracheal intubation were collected. Results: Eighty patients were treated with PB over a 1-year period. Thirty-nine patients were analyzed. Median loading dose was 19.9 (Interquartile Range 19.1-20.0) mg/kg with a median post load level of 21.7 mcg/mL (IQR 18.3-25.8) mcg/mL. One patient (2.6%) had electrographic evidence for early PTS. PB was discontinued in 4 (10.3%) patients out of concern for over sedation. One patient required endotracheal intubation after rapid PB loading. Conclusion: The frequency of early PTS was low when PB was used as primary ACP in patients with TBI at risk for AWS. Over sedation is a potential adverse effect that should be considered in the choice of ACP. No conclusions can be drawn as to the effectiveness of PB in preventing AWS.
The estrogen and progesterone sequential regimen was adopted. The drug was estradiol tablets/estradiol didroxyprogesterone tablets (Femoston). Red tablets (estradiol, 2mg/d) were taken in the first 14 days, and gray tablets (estradiol, 2mg/d, dydrogesterone,10 mg/d) were taken in the last 14 days. 28 days was a course of treatment, and 3 courses of treatment were taken.
During the first stage of treatment, participants will receive four weekly clinician support sessions or 9 weeks (whichever occurs first), slow responders that are then randomized to full PE will have sessions once a week for eight weeks. During these 60 minute sessions, participants will practice in vivo and imaginal exposure and continue these exposure exercises every day at home.
The invention provides a gRNA targeting VEGFR2 and application thereof, wherein a gRNA targeting sequence is selected from a 5' end region of No. 3 exon, no. 15 exon or No. 17 exon of VEGFR 2. The invention also provides an expression vector for expressing the gRNA, a CRISPR-Cas system for targeting VEGFR2 and application of the expression vector and the CRISPR-Cas system. Compared with the prior art, the gRNA has higher editing efficiency on VEGFR2, can effectively inhibit the expression of VEGFR2, and has better treatment effect on diseases caused by the over-expression of VEGFR2, such as cancer, diabetic nephropathy, rheumatoid arthritis, psoriasis skin, ovarian hyperstimulation syndrome, proliferative diabetic retinopathy, mature retinopathy and age-related wet macular degeneration; and the invention utilizes non-viral vectors, and has higher safety.
PROBLEM TO BE SOLVED: To obtain the subject cosmetic capable of removing dirt and stratified corneal calls of the skin and synergistically enhancing its effects used after gommage, by including a solid oil and a silicone oil. SOLUTION: This cosmetic is capable of forming silicon oil membranes on the skin to make the skin smooth and facilitate massage and capable of rubbing off the dirt and old corneal layers of the skin together with a solid oil by including (A) solid oil (e.g. paraffin, microcrystalline wax) and (B) silicone oil (e.g. octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane). Furthermore, addition of (C) powder (e.g. cellulose powder) affords a highly cleansing cosmetic. It is preferable that the compounding ratio of the components A to C is each 0.01-50 wt.%.
BACKGROUND: Once-weekly efanesoctocog alfa provides high sustained factor VIII activity with superior bleeding prevention as compared with prestudy factor VIII prophylaxis in previously treated patients 12 years of age or older with severe hemophilia A. Data on outcomes of efanesoctocog alfa treatment in children younger than 12 years of age with severe hemophilia A are limited.
METHODS: We conducted a phase 3, open-label study involving previously treated patients younger than 12 years of age with severe hemophilia A. Patients received prophylaxis with once-weekly efanesoctocog alfa (50 IU per kilogram of body weight) for 52 weeks. The primary end point was the occurrence of factor VIII inhibitors (neutralizing antibodies against factor VIII). Secondary end points included annualized rates of treated bleeding episodes, bleeding treatment, safety, and pharmacokinetics.
RESULTS: A total of 74 male patients were enrolled (38 with an age of <6 years and 36 with an age of 6 to <12 years). No factor VIII inhibitors developed. Most adverse events were nonserious. No serious adverse events that were assessed by the investigator as being related to efanesoctocog alfa were reported. In the 73 patients treated according to the protocol, the median and model-based mean annualized bleeding rates were 0.00 (interquartile range, 0.00 to 1.02) and 0.61 (95% confidence interval, 0.42 to 0.90), respectively. A total of 47 patients (64%) had no treated bleeding episodes, 65 (88%) had no spontaneous bleeding episodes, and 61 (82%) had no episodes of bleeding into joints. A total of 41 of 43 bleeding episodes (95%) resolved with one injection of efanesoctocog alfa. Mean factor VIII activity at steady state was more than 40 IU per deciliter for 3 days and more than 10 IU per deciliter for almost 7 days after dose administration. The geometric mean terminal half-life was 40.0 hours.
CONCLUSIONS: In children with severe hemophilia A, once-weekly prophylaxis with efanesoctocog alfa provided high sustained factor VIII activity in the normal to near-normal range (>40 IU per deciliter) for 3 days and more than 10 IU per deciliter for almost 7 days after administration, leading to effective bleeding prevention. Efanesoctocog alfa was associated with mainly nonserious adverse events. (Funded by Sanofi and Sobi; XTEND-Kids ClinicalTrials.gov number, NCT04759131.).
PURPOSE: To obtain an oral medicinal molded body from which an active compd. is released in the colon in a controlled state. CONSTITUTION: This oral medicinal molded body is composed of at least one kind of active compd. and at least one kind of enveloping material which envelopes the active compd. and is made of at least one kind of film forming agent insoluble in water and digestive fluid. The enveloping material may further contain at least one kind of cyclodextrin and/or at least one kind of its deriv.
Acute bacterial meningitis (ABM) is associated with severe morbidity and mortality. The most prevalent pathogens in community-acquired ABM are Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Other pathogens may affect specific patient groups, such as newborns, older patients, or immunocompromised patients. It is well established that ABM is associated with elevated intracranial pressure (ICP). However, the role of ICP monitoring and management in the treatment of ABM has been poorly described.An electronic search was performed in four electronic databases: PubMed, Web of Science, Embase, and the Cochrane Library. The search strategy chosen for this review used the following terms: Intracranial Pressure AND (management OR monitoring) AND bacterial meningitis. The search yielded a total of 403 studies, of which 18 were selected for inclusion. Eighteen studies were finally included in this review. Only one study was a randomized controlled trial. All studies employed invasive ICP monitoring techniques, whereas some also relied on assessment of ICP-based on clinical and/or radiological observations. The most commonly used invasive tools were external ventricular drains, which were used both to monitor and treat elevated ICP. Results from the included studies revealed a clear association between elevated ICP and mortality, and possibly improved outcomes when invasive ICP monitoring and management were used. Finally, the review highlights the absence of clear standardized protocols for the monitoring and management of ICP in patients with ABM. This review provides an insight into the role of invasive ICP monitoring and ICP-based management in the treatment of ABM. Despite weak evidence certainty, the present literature points toward enhanced patient outcomes in ABM with the use of treatment strategies aiming to normalize ICP using continuous invasive monitoring and cerebrospinal fluid diversion techniques. Continued research is needed to define when and how to employ these strategies to best improve outcomes in ABM.